Abstract
Intratumoral delivery of drugs, enabling increased local concentrations in the tumor microenvironment, might be superior to systemic administration in promoting antitumor activity and minimizing the systemic side effects of some drugs. Unfortunately, not all human cancers are amenable to drug injection into the tumor site. Lung cancers are candidate tumors for taking advantage of local delivery, being accessible via the endobronchial space by aerosol administration. Inhalation of aerosolized drugs is a promising option in the management of lung diseases and currently represents the standard treatment for asthma and chronic obstructive pulmonary disease. Besides a high local concentration, the advantages of aerosol administration of medications to the lung include reduced distribution to the systemic circulation and pain- and needle-free delivery. Several therapeutic agents have been explored for inhalation in lung malignancies, including chemotherapeutic agents, cytokines, Toll-like receptor agonists, monoclonal antibodies, genes and antisense oligonucleotides, demonstrating the feasibility of aerosol delivery, the potential antitumor effects and the reduced side effects compared with systemic treatment. In this review we summarize preclinical and clinical data regarding aerosol delivery of these drugs in the treatment of lung cancer.
Keywords: Aerosol delivery, chemotherapy, cytokines, gene therapy, lung cancer, monoclonal antibodies, Toll-like receptor agonists.
Current Cancer Drug Targets
Title:Aerosol Delivery in the Treatment of Lung Cancer
Volume: 15 Issue: 7
Author(s): Chiara Storti, Valentino Le Noci, Michele Sommariva, Elda Tagliabue, Andrea Balsari and Lucia Sfondrini
Affiliation:
Keywords: Aerosol delivery, chemotherapy, cytokines, gene therapy, lung cancer, monoclonal antibodies, Toll-like receptor agonists.
Abstract: Intratumoral delivery of drugs, enabling increased local concentrations in the tumor microenvironment, might be superior to systemic administration in promoting antitumor activity and minimizing the systemic side effects of some drugs. Unfortunately, not all human cancers are amenable to drug injection into the tumor site. Lung cancers are candidate tumors for taking advantage of local delivery, being accessible via the endobronchial space by aerosol administration. Inhalation of aerosolized drugs is a promising option in the management of lung diseases and currently represents the standard treatment for asthma and chronic obstructive pulmonary disease. Besides a high local concentration, the advantages of aerosol administration of medications to the lung include reduced distribution to the systemic circulation and pain- and needle-free delivery. Several therapeutic agents have been explored for inhalation in lung malignancies, including chemotherapeutic agents, cytokines, Toll-like receptor agonists, monoclonal antibodies, genes and antisense oligonucleotides, demonstrating the feasibility of aerosol delivery, the potential antitumor effects and the reduced side effects compared with systemic treatment. In this review we summarize preclinical and clinical data regarding aerosol delivery of these drugs in the treatment of lung cancer.
Export Options
About this article
Cite this article as:
Storti Chiara, Noci Le Valentino, Sommariva Michele, Tagliabue Elda, Balsari Andrea and Sfondrini Lucia, Aerosol Delivery in the Treatment of Lung Cancer, Current Cancer Drug Targets 2015; 15 (7) . https://dx.doi.org/10.2174/1568009615666150602143751
DOI https://dx.doi.org/10.2174/1568009615666150602143751 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry Compound Ranking Based on a New Mathematical Measure of Effectiveness Using Time Course Data from Cell-Based Assays
Combinatorial Chemistry & High Throughput Screening SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target
Current Pharmaceutical Design Self-Assembly of DNA and Cell-Adhesive Proteins onto pH-Sensitive Inorganic Crystals for Precise and Efficient Transgene Delivery
Current Pharmaceutical Design Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
Reviews on Recent Clinical Trials Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies
Clinical Cancer Drugs Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?
Current Molecular Medicine Is α7-nAChR a Possible Target for Lung Cancer and Malignant Pleural Mesothelioma Treatment?
Current Drug Targets Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Molecular Pathophysiology of Cavernous Nerve Injury and Identification of Strategies for Nerve Function Recovery After Radical Prostatectomy
Current Drug Targets Gender Differences in Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery Cyclodextrin-based Polymeric Nanoparticles as Efficient Carriers for Anticancer Drugs
Current Pharmaceutical Biotechnology PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology The Rationale for Repurposing Sildenafil for Lung Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance
Current Drug Targets Longevity Pathways (mTOR, SIRT, Insulin/IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration
Current Topics in Medicinal Chemistry Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC)
Reviews on Recent Clinical Trials